Caris Life Sciences, Inc.(CAI)Earnings, Financials & Key Ratios

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection.

ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations Center (SOC) services to local government entities across the Commonwealth.

ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.